COMPANY

Mediar Therapeutics

He joined Mediar from Pfizer, where he spent more than 20 years focused on drug discovery and development. From company website Source · Oct 12, 2026

Keywords: drug discovery Diffuse Cutaneous Systemic Sclerosis Idiopathic Pulmonary Fibrosis Diabetic Kidney Disease MTX-463 MTX-474 MTX-439

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $37.85M (Form D filed Dec 23, 2025). SEC Form D 0001766784-25-000002 (Dec 23, 2025)
Evidence (1 event)
- Dec 23, 2025 · SEC Form D 0001766784-25-000002
  Name of Issuer: Mediar Therapeutics, Inc.; CIK: 1766784; Address: Boston, MA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75699630; Total Amount Sold: 37849815; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Deal Lilly deal · $99M (upfront + near-term milestones) · announced Jan 10, 2025 Company release ↗
Source quote
- Jan 10, 2025 · Company release ↗
  “Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones”

From the company’s own releases; this list is partial. All raises and deals

May 19, 2026 Trial start Phase 1: Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease source ↗
Apr 16, 2026 Trial start Phase 2: EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) source ↗
Feb 18, 2026 Trial start Phase 1: Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males source ↗
May 5, 2025 Trial start Phase 2: WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) source ↗
Jul 10, 2024 Trial start Phase 1: A First-in-Human Safety Trial of MTX-474 source ↗
Apr 15, 2024 Trial start Phase 1: A First-in-Human Safety Trial of MTX-463 source ↗

2027-05 (ESTIMATED) · Phase 1 · Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease · NCT07473323
2027-08 (ESTIMATED) · Phase 2 · WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) · NCT06967805
2028-12 (ESTIMATED) · Phase 2 · EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) · NCT07287670

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07287670	EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Phase 2	Recruiting	Apr 16, 2026	2028-12 (estimated)
NCT06967805	WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Recruiting	May 5, 2025	2027-08 (estimated)
NCT07473323	Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease	Phase 1	Recruiting	May 19, 2026	2027-05 (estimated)
NCT07450521	Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males	Phase 1	Completed	Feb 18, 2026	Mar 11, 2026 (actual)
NCT06535841	A First-in-Human Safety Trial of MTX-474	Phase 1	Completed	Jul 10, 2024	Apr 24, 2025 (actual)
NCT06401213	A First-in-Human Safety Trial of MTX-463	Phase 1	Completed	Apr 15, 2024	Nov 15, 2024 (actual)